This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Login
Register Now to Watch
Buprenorphine for Cancer Pain: Results from a Systematic Review
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Login
Register Now to Watch
The following questions and topics will be covered in this presentation.
Buprenorphine for Cancer Pain: Results from a Systematic Review
1) Should buprenorphine be the first line for the management of acute cancer pain?
a) Yes, because high-quality evidence suggests it is superior to full MOR agonists.
b) Yes, because very low to moderate quality evidence suggests it is equivalent to full MOR agonists, with morphine being the most examined.
c) No, because there is no evidence supporting its use for acute cancer pain.
d) No, because it is less effective than full MOR agonists like morphine.
2) What remain critical gaps in the literature on buprenorphine for cancer pain?
a) The effectiveness of buprenorphine compared to non-opioid pain medications.
b) The impact of buprenorphine on patients with short life expectancies.
c) The differences in the use of breakthrough medication between buprenorphine and full MOR agonists.
d) Both B and C